| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002290 | American Journal of Ophthalmology | 2013 | 8 Pages |
Abstract
Reduced-fluence PDT monotherapy for PCV effectively improved and maintained the VA over a 24-month period, even in eyes with a baseline VA better than 20/40. In addition, the number of treatments could be much smaller as compared with intravitreal injection of anti-vascular endothelial growth factor agents.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ayana Yamashita, Fumio Shiraga, Chieko Shiragami, Yukari Shirakata, Atsushi Fujiwara,